U.S. Markets closed
S&P Futures
4,122.25+4.25(+0.10%)Dow Futures
33,679.00+55.00(+0.16%)Nasdaq Futures
13,807.00+8.25(+0.06%)
Kaleido Biosciences, Inc. (KLDO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.87-0.25 (-3.51%)
At close: 4:00PM EDT
6.89 +0.02 (0.29%)
After hours: 5:16PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 7.12 |
| Open | 7.22 |
| Bid | 6.80 x 900 |
| Ask | 6.89 x 900 |
| Day's Range | 6.82 - 7.31 |
| 52 Week Range | 5.04 - 20.50 |
| Volume | 175,102 |
| Avg. Volume | 298,331 |
| Market Cap | 302.364M |
| Beta (5Y Monthly) | -0.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.44 |
| Earnings Date | May 12, 2021 - May 17, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.57 |
- Yahoo Finance Video
Biotech company Kaleido develops oral therapy for COVID-19
Dan Menichella, Kaleido CEO, joins Yahoo Finance’s Anjalee Khemlani, Alexis Christoforous and Kristin Myers to discuss the utilization of oral therapeutic KB109 for COVID-19 and emerging variants.
- Zacks
CytoDyn (CYDY) Files New Protocol With FDA for COVID-19 Study
CytoDyn (CYDY) submits a new protocol with the regulatory body in the United States to study a higher dose of leronlimab for severely-infected COVID-19 patients.
- Zacks
Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & More
The biotech sector gains prominence with new product approvals from bluebird (BLUE)/Bristol Myers Squibb (BMY) and other coronavirus updates.
© 2021 Verizon Media. All rights reserved.
